Skip to main content

Table 2 Therapeutic intervention and follow-up in patients with somatotropinoma

From: Sporadic and genetic forms of paediatric somatotropinoma: a retrospective analysis of seven cases and a review of the literature

Patient Genetic mutation IGF1 (μg/L) and MRI at diagnosis First-type therapy Second-type therapy Third-type therapy Fourth-type therapy Control of disease Last IGF1 (μg/L) and MRI F-U (Years)
1 MAS 406 (+3SD) Hyperplasia 565 (+4SD) Octreotide LAR 30 mg (monthly- 18 months) + Cabergoline 1 mg/week Pegvisomant 20 mg/day   C 333 (-1SD) NA 7
2 MENI Invasive Macroadenoma (36 × 27 × 28 mm) 1259 (+4SD) Trans-sphenoidal surgery Octreotide LAR 30 mg monthly (6 months - growth of adenoma with visual disturbance; 3 surgeries) + Cabergoline with visual (1 mg/week) Proton therapy NC 689 (+2.5SD) 14 × 10 mm (-68%) 3
3 AIP Invasive Macroadenoma (21 × 26 mm) 997 (+4SD) Lanreotide LAR 90 mg monthly (6 months) Octreotide LAR 30 mg monthly + cabergoline (1 mg/week) Transphenoidal surgery   NC 1184 (+4SD) 10 × 12 × 9 mm (-50%) 4
4 AIP Invasive Macroadenoma (16 × 21 × 11 mm) 934 (+4SD) Lanreotide LAR 60 mg monthly (6 months) Transphenoidal surgery    C 451 (0SD) No visible adenoma 6
5 Negative genetic analysis (Carney, MEN1, AIP) Non invasive macroadenoma (19 × 14 × 20 mm) Lanreotide LAR 60 mg monthly     C 282 (+1SD) No visible adenoma 4
6 Negative genetic analysis (MEN1, AIP) 777 (+3SD) Invasive macroadenoma (26 × 26 × 32 mm) Octreotide LAR 30 mg monthly (6 months) added to the previous Dopamine agonist treatment (Cabergoline 1,5 mg/week)     NC 717(+3SD) 34 × 21 × 23 mm (+6%) 2
7 Negative genetic analysis (Carney, MEN1, AIP) 574 (+4SD) Microadenoma (7,6 × 9 × 7,5 mm) Trans-sphenoidal surgery     C 504 (+1,5 SD) No visible adenoma 4